Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection

Avouac, Jérôme; Ghossan, R.; Tabaa, Omar Al; Combier, Alice; Steelandt, Alexia; Thomas, M.; Fogel, O.; Mariaggi, Alice Andrée; Méritet, Jean–François; Rozenberg, Flore; Moltó, Anna; Miceli, Corinne; Allanore, Yannick

doi:10.1093/rheumatology/keac201

Search citation statements

Order By: Relevance

Paper Sections

Select...

Importance Of Sars-cov-2 Spike Antibodies and B Cell Reconst...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A first clinical experience showed increased antibody response in RTX-treated patients following a symptomatic COVID-19 infection. 15 Finally, in patients receiving monoclonal antibodies, the efficacy may largely vary according to the variants, and the optimal dose and timing of reinjection are not firmly established.…”

Section: Importance Of Sars-cov-2 Spike Antibodies and B Cell Reconst...mentioning

confidence: 99%

Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19

Thomas

Avouac

2023

J Rheumatol

View full text Add to dashboard Cite

show abstract

Section: Importance Of Sars-cov-2 Spike Antibodies and B Cell Reconst...mentioning

confidence: 99%

Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19

Thomas

Avouac

2023

J Rheumatol

View full text Add to dashboard Cite

show abstract

Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?

Ghossan,

Al Tabaa,

Combier

et al. 2023

Rheumatology

View full text Add to dashboard Cite

Objective To determine whether persistent complete B cell (BC) depletion was associated with a better clinical response in rheumatoid arthritis (RA) patients long-term treated with rituximab (RTX). Methods We conducted a retrospective study including RA patients admitted for a new infusion between 2019 and 2021. The primary end point was the comparison of the mean DAS28-CRP at each of the 4 last infusion visits between patients with persistent complete BC depletion (mean CD19 counts <18/µL at each of the last 4 visits) or without persistent complete BC depletion (mean CD19 counts of the last 4 visits ≥18/µL). Secondary endpoints included DAS28, pain/fatigue VAS, CRP, gammaglobulins and the frequency of self-reported RA flares. Results Of the 126 patients in maintenance therapy with RTX (exposure period: 76 ± 5 months, n 14 ± 7 infusions received), 43 (34%) had persistent complete BC depletion at each of the 4 last infusions. The mean DAS28-CRP calculated at each of the 4 last infusion visits did not significantly differ according to persistence or not of complete BC depletion. This result remained unchanged after adjusting for antibody status, number of previous therapies, number of RTX infusion and cumulative RTX dose. All secondary outcomes were also not significantly different between both groups. Conclusion Maintaining complete BC depletion does not appear to be a therapeutic target to achieve in RA patients in long-term maintenance therapy with RTX. There is a limited benefit of monitoring CD19 in RA patients long term treated with RTX and having achieved low disease activity/remission.

show abstract

Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection

Cited by 2 publications

References 6 publications

Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19

Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19

Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?

Contact Info

Product

Resources

About